Background summary: The policy reviews the role of standardized biopsy protocols and advanced tools in upper GI practice. The Seattle Protocol (four-quadrant biopsies at spacing adjusted by dysplasia status) and the Sydney protocol for H. pylori sampling are included as sampling guidance. Studies of EndoFLIP (impedance planimetry) report its capability to measure cross-sectional area, pressure, and distensibility intra-procedurally (used in POEM, tailored fundoplication, pyloric assessment, Zenker's diverticulum), with promising but preliminary results and calls for larger standardized studies.
Guideline and study points: major guideline and evidence excerpts note that ESD may be appropriate for Barrett's lesions with features suspicious for submucosal invasion, large/bulky nodularity, recurrent visible dysplasia, or lesions > 2.0 cm, while EMR is appropriate for smaller lesions (≤ 1.0 cm), and that ESD provides higher en bloc, R0 and curative rates but longer procedure time and higher perforation risk; a multicenter retrospective series showed markedly lower recurrence with ESD versus EMR (recurrence ~ 3.5% ESD vs 31.4% EMR).
Limitations: the policy emphasizes study limitations — small sample sizes, single-operator/center series, variability in EndoFLIP measurement volumes (30- vs 40-ml), confounding factors such as hiatal hernia, inconsistent case definitions (ERD vs NERD), and the need for standardized metrics and larger multicenter trials to validate EndoFLIP and some procedural innovations. Additionally, an RCT of fibrin glue after gastric ESD in high-risk patients found no reduction in overall bleeding (though acute bleeding was lower), illustrating mixed or limited high-quality evidence for some adjunctive interventions.